FLT3-Mutated AML

FLT3-Mutated AML

OncUpdates episode 4 features experts discussing FLT3-Positive AML targeted therapy from diagnosis through long-term management.

FLT3-Mutated AML

07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates episode 3 featuring experts discussing FLT3-mutated AML, maintenance therapy, triplet regimens, and relapse management.

FLT3-Mutated AML

07/27/2026

Ep. 3: FLT3-Mutated AML: Maintenance Therapy, Triplet Regimens, and Relapse Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss FLT3 inhibitors expanding treatment options in acute myeloid leukemia at OncUpdates.

FLT3-Mutated AML

07/24/2026

Ep. 2: FLT3 Inhibitors Continue to Expand Treatment Opportunities in Acute Myeloid Leukemia

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of five medical professionals discussing FLT3-mutated AML treatment strategies in a clinical setting.

FLT3-Mutated AML

07/23/2026

Ep. 1: Optimizing FLT3-Mutated AML Through Precision Testing and Targeted Therapy

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of five leukemia specialists discussing FLT3 inhibitors in AML treatment, featuring Dr. Nicholas Short, Dr. Uma Borate, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Naval Dayer.

FLT3-Mutated AML

07/13/2026

Leukemia Specialists Review the Role of FLT3 Inhibitors Across AML Treatment Settings

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD